Literature DB >> 11125325

Purpura fulminans in a patient with malaria.

J E Keri1, K Thomas, B Berman, A Falabella.   

Abstract

A case of purpura fulminans in a 44 year old woman infected with malaria is reported. The patient had laboratory findings consistent with disseminated intravascular coagulation and a severe eruption consisting of hemorrhagic bullae and crusts. This case is presented to elucidate another cutaneous manifestation of malaria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11125325

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  6 in total

1.  Purpura fulminans due to imported falciparum malaria.

Authors:  Philippe Corne; Fabrice Bruneel; Christine Biron-Andreani; Olivier Jonquet
Journal:  Intensive Care Med       Date:  2008-07-08       Impact factor: 17.440

2.  Malaria - the Master Masquerader.

Authors:  V Upreti; V Gera; L C Chamania; R A Shetty; M Chopra
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 3.  Plasmodium falciparum cerebral malaria complicated by disseminated intravascular coagulation and symmetrical peripheral gangrene: case report and review.

Authors:  M E Liechti; V Zumsteg; C F R Hatz; T Herren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-08-21       Impact factor: 3.267

4.  Cutaneous manifestations of infection in returning travelers.

Authors:  Matthew Eldridge; Stuart H Cohen
Journal:  Curr Infect Dis Rep       Date:  2014-10       Impact factor: 3.663

Review 5.  Dysregulation of coagulation in cerebral malaria.

Authors:  Christopher Alan Moxon; Robert Simon Heyderman; Samuel Crocodile Wassmer
Journal:  Mol Biochem Parasitol       Date:  2009-03-26       Impact factor: 1.759

6.  Lipoxin A₄ and 15-epi-lipoxin A₄ protect against experimental cerebral malaria by inhibiting IL-12/IFN-γ in the brain.

Authors:  Nathaniel Shryock; Cortez McBerry; Rosa Maria Salazar Gonzalez; Steven Janes; Fabio T M Costa; Julio Aliberti
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.